- Home
- LUNG vs ABVC Comparison
LUNG vs ABVC Comparison
Compare LUNG & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- ABVC
- Stock Information
- Founded
- LUNG 1995
- ABVC 2015
- Country
- LUNG United States
- ABVC United States
- Employees
- LUNG 291
- ABVC N/A
- Industry
- LUNG Industrial Specialties
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- ABVC Health Care
- Exchange
- LUNG Nasdaq
- ABVC Nasdaq
- Market Cap
- LUNG 63.6M
- ABVC 52.1M
- IPO Year
- LUNG 2020
- ABVC N/A
- Fundamental
- Price
- LUNG $1.98
- ABVC $2.91
- Analyst Decision
- LUNG Buy
- ABVC
- Analyst Count
- LUNG 7
- ABVC 0
- Target Price
- LUNG $7.66
- ABVC N/A
- AVG Volume (30 Days)
- LUNG 827.7K
- ABVC 84.5K
- Earning Date
- LUNG 10-29-2025
- ABVC 11-13-2025
- Dividend Yield
- LUNG N/A
- ABVC N/A
- EPS Growth
- LUNG N/A
- ABVC N/A
- EPS
- LUNG N/A
- ABVC N/A
- Revenue
- LUNG $90,549,000.00
- ABVC $391,242.00
- Revenue This Year
- LUNG $10.30
- ABVC $735.18
- Revenue Next Year
- LUNG $14.72
- ABVC N/A
- P/E Ratio
- LUNG N/A
- ABVC N/A
- Revenue Growth
- LUNG 18.24
- ABVC 186.84
- 52 Week Low
- LUNG $1.47
- ABVC $0.40
- 52 Week High
- LUNG $9.37
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- LUNG 62.99
- ABVC 47.60
- Support Level
- LUNG $1.56
- ABVC $2.86
- Resistance Level
- LUNG $1.67
- ABVC $3.05
- Average True Range (ATR)
- LUNG 0.15
- ABVC 0.15
- MACD
- LUNG 0.03
- ABVC -0.02
- Stochastic Oscillator
- LUNG 33.58
- ABVC 26.59
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.